On August 24, 2022 PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune and Infectimune T cell activating technologies, reported that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") to provide up to a $35.0 million term loan (Press release, PDS Biotechnology, AUG 24, 2022, View Source [SID1234618607]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to partner with Horizon, a leading specialty finance company that has an extensive history of supporting innovative life science companies," said Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. "We anticipate a number of important milestones across our oncology and infectious disease programs. This transaction immediately strengthens our balance sheet and provides the financial resources necessary to advance the company’s clinical pipeline. We look forward to our meeting with the U.S. Food and Drug Administration this quarter to discuss the registrational trial design for our lead program."

As part of the financing, PDS Biotech received an initial tranche of $25 million at the close. The Company has an option to receive an additional $10 million. Each advance of the loan will be repaid in 48 monthly payments consisting of 24 monthly payments of interest only, followed by 24 monthly payments of principal and accrued interest. In connection with the financing, PDS Biotech issued Horizon warrants to purchase up to 4% of the loan amount, 381,625 of its common shares at an exercise price of $3.6685 per share. Proceeds will be used to support the ongoing clinical development of PDS0101 and other product candidates within the company’s pipeline and for general working capital purposes.

Further information with respect to the debt financing agreement with Horizon will be contained in a current report to be filed on Form 8-K by PDS Biotechnology with the Securities and Exchange Commission.

Conference Call and Webcast
The conference call is scheduled for Thursday, August 25, 2022 at 8:00 AM EDT. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and reference conference ID 13732262. To access the webcast, please use the following link. The event will be archived in the investor relations section of PDS Biotech’s website for six months.

On August 24, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 2:30 p.m. ET (Press release, Surface Oncology, AUG 24, 2022, View Source [SID1234618606]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at View Source In addition, a replay of the webcast will be available on the company’s website following the presentation.

On August 24, 2022 GNS, the leader in the use of "Digital Twins" and Causal AI & biosimulation technology for biopharmaceutical drug discovery and development, and Servier, a global pharmaceutical group, reported a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM) (Press release, Servier, AUG 24, 2022, View Source [SID1234618605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This collaboration furthers Servier’s goal to accelerate its drug discovery and clinical development efforts through AI and biosimulation and other digital initiatives," said Claude Bertrand, EVP of Research and Development at Servier. "We believe GNS’ Digital Twin and unique causal AI models will help our research and early development group improve our understanding of MM disease biology and, ultimately, transform our drug discovery and clinical development process".

"We are delighted to collaborate with Servier to help advance research in MM and leverage our Gemini Digital Twin patient models to help uncover novel insights and reveal the hidden biological circuity of this disease," said Joe Donahue, Chief Business Officer at GNS. "Working together with the outstanding Servier team, we hope to make a difference in the lives of patients with MM."

The collaboration will address key questions about how MM progresses in different patient subpopulations, including discovering what are the most synergistic pathways for new combination therapies and will help Servier gain insights that can advance their translational and clinical development efforts. This work will initially leverage the GNS Gemini Digital Twin for MM developed using the rich clinico-genomic data from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study.

GNS’ MM Digital Twin leverages the rich patient multi-modal data generated by MMRF to create a transparent, accurate, quantified representation of complex biological mechanisms, revealing new circuitry of human disease. By conducting biosimulations, which are essentially computational experiments, one can discover new drug targets and disease mechanisms, and can also determine which drug candidates are more effective than others and why certain molecular profiles of patients lead to better and more durable response. Ultimately, the MM Digital Twins will radically change how Pharma R&D is conducted by helping to accelerate the identification of new targets and target combinations, new biomarkers, and enabling the in silico design of better trials.

On August 24, 2022 xCures, Inc. reported to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study (Press release, xCures, AUG 24, 2022, View Source [SID1234618604]). NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. The study involves patients with recently diagnosed metastatic pancreatic adenocarcinoma who are scheduled to receive chemotherapy treatment with gemcitabine and abraxane.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. By combining xCures’ records collection, virtual screening, eConsent and data structuring technology with Vault Health’s state-of-the-art suite of patient-centric clinical research services, including telemedicine, remote sample collection, and logistics, the NEAAR-001 protocol can be delivered directly to patients in the convenience of their homes.

"We are thrilled to partner with Vault Health and Faeth Therapeutics to help recently diagnosed pancreatic cancer patients access the NEAAR-001 study as a patient-centric and decentralized clinical trial," said Mika Newton, CEO of xCures. "Importantly, our combined efforts will enable cancer patients from diverse populations and socioeconomic backgrounds to participate in research."

"We are excited to bring our patient-first philosophy to simplify the journey and offer clinical research as a care option to pancreatic cancer patients," said Alexander Pastuszak, MD, PhD, President of Clinical Care and Chief Medical & Scientific Officer, Vault Health. "Together with xCures and Faeth Therapeutics, we are looking forward to rapidly recruiting and enrolling patients where they are, reducing recruitment timelines and costs, and increasing patient engagement."

"Faeth is dedicated to curing every cancer for every patient, and this partnership with Vault Health and xCures will make it easier for many more people with metastatic pancreatic cancer to access our precision nutrition intervention," said Faeth co-founder and CEO Anand Parikh. "Faeth would like to offer access to our clinical trials to a wider subset of patients, and by enabling remote access to the NEAAR-001 study, they can enroll in our trial without having to leave home, regardless of where they’re based."

On August 24, 2022 ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, reported that L1 Capital Global Opportunities Master Fund ("L1") has exercised Options over 1,000,000 new ordinary shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £50,000 (Press release, ImmuPharma, AUG 24, 2022, View Source [SID1234618603]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New Ordinary Shares and Admission

The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company’s existing issued Ordinary Shares.

An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Tuesday 30 August 2022.

The New Ordinary Shares represent 0.30% of the Company’s enlarged issued share capital.

Total Shares in Issue

For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company’s total issued share capital will consist of 328,403,115 Ordinary Shares with a nominal value of 1p each.

This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.